Mogrify Extends Series A Financing to 46 Million USD - European Pharmaceutical Manufacturer
| ERGO Stock | USD 0.0002 0.00 0.00% |
About 52% of Entia Biosciences' investor base is interested to short. The analysis of overall sentiment of trading Entia Biosciences pink sheet suggests that many investors are impartial at this time. Entia Biosciences' investing sentiment overview a quick insight into current market opportunities from investing in Entia Biosciences. Many technical investors use Entia Biosciences stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Entia |
Mogrify Extends Series A Financing to 46 Million USD European Pharmaceutical Manufacturer
Read at news.google.com
 |
Entia Biosciences Fundamental Analysis
We analyze Entia Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Entia Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Entia Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Entia Biosciences is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Entia Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Entia Biosciences pink sheet to make a market-neutral strategy. Peer analysis of Entia Biosciences could also be used in its relative valuation, which is a method of valuing Entia Biosciences by comparing valuation metrics with similar companies.
Peers
Entia Biosciences Related Equities
| PLX | Protalix Biotherapeutics | 1.64 |
| ||
| OTLK | OUTLOOK THERAPEUTICS | 2.48 |
| ||
| HRTX | Heron Therapeuti | 3.55 |
| ||
| HOOK | Hookipa Pharma | 7.88 |
|
Other Information on Investing in Entia Pink Sheet
Entia Biosciences financial ratios help investors to determine whether Entia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entia with respect to the benefits of owning Entia Biosciences security.